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The inflammatory autoimmune disease systemic lupus erythematosus (SLE) can involve the brain, including 
increasing stroke risk for reasons that remain incompletely 
understood.1
Cerebral small vessel disease (SVD) is an intrinsic disorder 
of the brain’s perforating arterioles.2 Imaging features range 
from asymptomatic white matter hyperintensities (WMH) and 
other brain imaging biomarkers3 of SVD such as an increase 
in number and size of visible perivascular spaces (PVS) to 
symptomatic lacunar stroke, which accounts for ≈25% of 
ischemic strokes. Symptoms also include cognitive impair-
ment and dementia, depression, and balance problems.2
In sporadic SVD, inflammation and cell infiltrates are seen 
in the perforating arteriolar walls, and microglial activation is 
seen in the perivascular tissue on pathology.4 The source of 
the inflammation is not known, whether intrinsic or triggered 
by systemic processes. However, consistent with an inflamma-
tory component, SVD-related PVS are associated with raised 
plasma markers of inflammation in healthy older subjects.5 
Also, C-reactive protein (CRP), a common plasma marker of 
inflammation, was associated with lacunar infarcts in a recent 
large (n=519) study, independent of age and vascular risk fac-
tors.6 Thus, factors that contribute to endothelial damage, such 
as immune complex formation and complement activation/
deposition, and occur in SLE might trigger cerebrovascular 
inflammation in SLE.
We hypothesized that one explanation for increased stroke 
risk in patients with SLE could be via the effects of systemic 
inflammation on cerebral small vessel integrity. Our aims 
were to measure and compare imaging biomarkers of SVD 
Background and Purpose—Systemic lupus erythematosus (SLE) increases stroke risk, but the mechanism is uncertain. This 
study aimed to determine the association between SLE and features on neuroimaging of cerebral small vessel disease 
(SVD), a risk factor for stroke.
Methods—Consecutive patients attending a clinic for SLE were recruited. All patients underwent brain magnetic resonance 
imaging; had blood samples taken for markers of inflammation, endothelial dysfunction, cholesterol, and autoantibodies; 
and underwent cognitive and psychiatric testing. The data were compared with sex- and age-matched healthy controls and 
patients with minor stroke. Features of SVD were measured, a total SVD score calculated, and associations sought with 
vascular risk factors, cognition, SLE activity, and disease duration.
Results—Fifty-one SLE patients (age: 48.8 years; SD: 14.3 years) had a greater total SVD score compared with healthy 
controls (1 versus 0; P<0.0001) and stroke patients (1 versus 0; P=0.02). There were higher perivascular spaces and deep 
white matter hyperintensity scores and more superficial brain atrophy in SLE patients versus healthy controls. Despite 
fewer vascular risk factors than similarly aged stroke patients, SLE patients had similar or more of some SVD features. 
The total SVD score was not associated with SLE activity, cognition, disease duration, or any blood measure.
Conclusions—In this data set, SLE patients had a high burden of SVD features on magnetic resonance imaging, particularly 
perivascular spaces. A larger longitudinal study is warranted to determine the causes of SVD features in SLE and clinical 
implications.   (Stroke. 2016;47:2722-2728. DOI: 10.1161/STROKEAHA.116.014330.)
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in patients with SLE with sex- and age-matched healthy con-
trols and patients with minor including lacunar stroke and, 
in patients with SLE, compute a total burden of SVD score 
and determine associations with vascular risk factors, plasma 
biomarkers of inflammation, endothelial dysfunction, choles-
terol, cognition, and clinical measures of SLE disease activity 
and damage.
Methods
Subjects
This cross-sectional brain magnetic resonance imaging (MRI) 
study prospectively recruited patients with SLE—including mem-
bers of the Scottish Lupus Exchange Database (UK Clinical Trials 
ID 15489)—who attended a regional specialist clinic between April 
and December 2014. The clinic reviews all patients diagnosed with 
SLE in one health region from the point of diagnosis onward. We 
recruited as consecutively as possible, and SLE patients repre-
sented a wide range of SLE, being of varying disease durations 
and severities. All patients were seen by a consultant rheumatolo-
gist; clinics were run jointly with a neurologist and renal physi-
cian. SLE was diagnosed according to updated American College 
of Rheumatology 1997 criteria.7 The project received research 
ethics committee approval (South-East Scotland Research Ethics 
Committee 01, 14/SS/0003), and all participants gave written 
informed consent.
We obtained control data from healthy volunteers aged between 
25 and 65 years, recruited by poster campaign at the same health 
region. Volunteers were recruited if they were native English speak-
ers, were not on any long-term medication, had not been diagnosed 
with any chronic medical condition including diabetes mellitus or 
hypertension, had not undergone previous cranial surgery, and were 
able to undergo brain MRI. The study was approved by the Lothian 
Research Ethics Committee (05/S1104/45), and subjects gave writ-
ten informed consent.
We also compared SLE patients to patients with first-ever minor 
(National Institutes of Neurological Disorders and Stroke scale <7 or 
nondisabling) stroke including those of small vessel (lacunar) type, 
recruited from the same health region via the regional stroke ser-
vice. The study was approved by the South-East Scotland Research 
Ethics Committee 01 (09/S1101/54). A stroke specialist determined 
the ischemic stroke subtype (lacunar or minor cortical) using the 
Oxfordshire Community Stroke Project8 clinical classification and 
confirmed by MRI.
Patients with SLE and both control groups were scanned with 
similar sequences on the same magnetic resonance scanner (details 
below) that underwent regular maintenance including daily quality 
assurance.
Vascular Risk Factors—SLE Patients
Medical histories including cardiovascular risk factors such as smok-
ing status, cerebrovascular events, hypertension, and diabetes melli-
tus were recorded. Height and weight were measured, and body mass 
index calculated. We measured blood pressure 3 times (before the 
MRI scan, after the scan, and at the end of the study visit) and noted 
antihypertensive medication. We dichotomized patients as hyperten-
sive or not and also classified them with the British Hypertension 
Society 6-point scale, from optimal to severe.9
SLE Activity and Damage Scores
SLE disease activity was assessed by an experienced rheumatol-
ogy nurse specializing in SLE, who interviewed each patient and 
had access to all medical data and blood results using the Systemic 
Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K)10 
and British Isles Lupus Assessment Group 2004 (BILAG)11 tools. 
Accumulated permanent damage was assessed with the Systemic 
Lupus International Collaborating Clinics (SLICC)12 tool.
Fatigue
Fatigue was assessed using the Fatigue Severity Scale13 with higher 
scores indicating more severe fatigue. The mean (SD) from normal 
healthy adults in the standardization sample was 2.3 (0.7).13
Cognitive and Psychiatric Assessments
We used Hospital Anxiety and Depression Scale,14 Montreal 
Cognitive Assessment,15 Addenbrooke’s Cognitive Examinations–
Revised,16 and Mini Mental State Examination17 to assess anxiety, 
depression, and cognitive function. The tests were administered by 
the study team, not to screen for neurolupus. However, before recruit-
ment, all SLE patients were seen at the SLE clinic that monitors for 
cerebral involvement in collaboration with neurology, and the 4 of 
51 with neuropsychiatric systemic lupus erythematosus (NPSLE) 
were diagnosed by a consultant neurologist with a special interest in 
neurolupus.
Magnetic Resonance Imaging
All patients and controls underwent neuroimaging at 1.5T (Signa 
HDx; GE, Milwaukee, WI). The following were acquired: axial T2, 
gradient-recalled echo, fluid-attenuated inversion recovery, sagittal 
T2, high-resolution coronal 3-dimensional T1 volume, and whole 
brain diffusion tensor MRI (please see Table I in the online-only Data 
Supplement for scan parameters). The diffusion tensor MRI scans 
were used to assess white matter microstructural integrity by measur-
ing mean diffusivity and fractional anisotropy.
Image Review and Visual Rating
All MRI scans were reviewed by a consultant neuroradiologist blind 
to all other data. Imaging features of SVD were defined per STRIVE 
guidelines.3 Deep and periventricular WMHs were coded 0 to 3 using 
the Fazekas18 scale and summed to give a total WMH score (0–6) per 
subject. Visible (enlarged) PVS are round (<3 mm) or linear depend-
ing on the orientation of the scan plane to the vessel19 and their inten-
sity is that of cerebrospinal fluid on T2-weighted MRI. They were 
assessed in the basal ganglia and centrum semiovale and scored as 
0 (none), 1 (1–10 PVS), 2 (11–20 PVS), 3 (21–40 PVS), and 4 (>40 
PVS) using a validated scale.19,20 Lacunes21 were defined as deep 
infarcts, distinguished from PVS because of their larger size (3–20 
mm), and their presence, including location in the brain, was noted 
and burden assessed by total count. We used the gradient-recalled 
echo scans and the simplified Brain Observer Microbleeds Scale22 
to count microbleeds. Cerebral atrophy was defined as enlargement 
of the ventricles (deep atrophy) and enlargement of the sulci (super-
ficial atrophy) and scored accordingly by classifying each participant 
on a validated 6-point scale23 against a template of normal reference 
brains. Three analysts did the rating; inter-rater agreement (κ) was 
0.66 to 1.0.
Total SVD Score
A total SVD score (range 0–4)24,25 was calculated from individual 
imaging features by awarding points as follows: 1 for any lacunes, 1 
for any microbleeds, 1 for moderate-to-severe PVS in the basal gan-
glia (grade 2–4), and 1 for WMHs (deep tissue: Fazekas score 2 or 
3 and/or periventricular: Fazekas score 3). The total SVD score cor-
related with both WMH volume (see below) (r=0.61; P<0.0001) and 
summed total Fazekas score (r=0.65; P<0.0001).
Volumetric Imaging Measures
Intracranial volume (ICV), cerebrospinal fluid, and brain tissue vol-
ume (BTV) were measured using Analyze 7.5 (http://analyzedirect.
com). The methods have been validated extensively.21 The BTV:ICV 
ratio was also used as a volumetric measure of atrophy; lower values 
reflecting lower brain tissue volume. The BTV:ICV ratio correlated 
with the atrophy scores (deep r=−0.72; P<0.0001 and superficial 
r=−0.74; P<0.0001). A volumetric measure of WMH (in mL) was 
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calculated using validated in-house software (MCMXXXVI, available 
from http://sourceforge.net/projects/bric1936/?source=directory), as 
described previously.26 The effect of head size was corrected for by 
dividing WMH volume by ICV. The WMH volume correlated with 
the total Fazekas score (r=0.83; P<0.0001).
Plasma Biomarkers
Participants had blood drawn on the day of MRI scanning to assess 
levels of the cytokine interleukin-6, endothelial dysfunction (von 
Willebrand Factor antigen and 2 measures of von Willebrand Factor 
activity: factor VIIIc and ristocetin cofactor), endothelial toxicity 
(homocysteine), cholesterol (total, high-density lipoprotein [HDL], 
and low-density lipoprotein), and antiphospholipid antibodies (anti-
cardiolipin IgG and IgM). Blood samples were analyzed in a fully 
accredited, major NHS laboratory (http://www.edinburghlabmed.
co.uk) that handles thousands of samples per day. Patients also had 
blood tests at recent clinic visits including that for SLE disease activ-
ity (C3, C4, and anti–double- stranded DNA) and for routine inflam-
matory markers (CRP and erythrocyte sedimentation rate [ESR]).
Statistical Analysis
We tested the association between total SVD score and the Fazekas 
score and, separately, the WMH volume. We compared age and sex 
pairwise (SLE to healthy controls; SLE to stroke) by Student t test and 
χ2 test, respectively. The individual features of SVD were compared 
for differences across the 3 subject groups by the Kruskal–Wallis test 
(the nonparametric equivalent of ANOVA); a post-test multiple com-
parisons test was used to identify the source of the difference.
We used ordinal logistic regression to test for associations between 
the total SVD score (range 0–4) and vascular risk factors (age, body 
mass index, cholesterol, and hypertension but not diabetes mellitus 
because no SLE patients had diabetes mellitus); plasma biomarkers 
of inflammation (interleukin-6, ESR, and CRP); endothelial dysfunc-
tion (von Willebrand Factor) and toxicity (homocysteine); rheumatol-
ogy scores (SLEDAI, BILAG, and SLICC); SLE disease duration; 
plasma markers of SLE activity (C3, C4, and anti–double-stranded 
DNA); antiphospholipid antibodies; and brain atrophy. Results are 
presented as odds ratios (ORs) with 95% confidence intervals (95% 
CIs). For transparency, we report all results regardless of the P value 
because this aids interpretation of the entire study, and we did not 
adjust the P values for multiple comparisons.27 A P value of <0.05 
was considered significant. All analyses were performed in R, version 
3.0.1 (http://www.r-project.org/).28
Results
Subjects
Of 55 consecutive patients with SLE, 51 (mean age: 48.8 
years; SD: 14.3 years) agreed to participate, including 47 
women (92%), and were compared with 51 healthy con-
trols (39 women [76%; P=0.06)) and 51 stroke patients (47 
women; P=0.99). Of the 4 SLE patients who did not partici-
pate, 2 had previous MRI claustrophobia and 2 did not give a 
reason. Clinical data are given in Table 1 and blood results in 
Table II in the online-only Data Supplement. Healthy controls 
were of similar age (mean age: 44.9 years; SD: 11.1 years; 
P=0.12), whereas the stroke patients were on-average 6 years 
older (mean age: 55.3 years; SD: 8.9 years; P=0.008) than 
the SLE patients. Four SLE patients had NPSLE (monitored 
by neurology, but none were being treated for active cen-
tral nervous system disease), 6 were current smokers, 9 had 
hypertension, none had diabetes mellitus, and 1 had a previous 
ischemic stroke. Eighteen were prescribed steroids at the time 
of assessment. There were significantly more smokers and 
hypertensives in the stroke group. The inflammatory markers 
ESR and CRP were raised in 22 out of 49 (45%) and 17 out of 
45 (38%) of SLE patients versus these tests’ normal reference 
ranges. Homocysteine was raised in 37 out of 45 (82%) SLE 
patients.
WMH, PVS, Lacunes, and Microbleeds in SLE
Periventricular and deep WMHs were seen in 49 out of 51 
(96%) and 36 out of 51 (70%) SLE patients, respectively. All 
SLE patients had visible PVS. Lacunes were seen in 5 (10%) 
and microbleeds in 2 (4%) SLE patients.
SVD Imaging Biomarkers Versus Healthy 
Controls and Stroke Patients
Compared with healthy controls, SLE patients had a greater 
total SVD score (Table 2) sustained across each 10-year age 
band (Figure), including more deep but not periventricular 
WMHs. Compared with stroke patients, the SLE patients also 
had a higher total SVD score, mostly because of having more 
PVS. SLE patients had more superficial, but not deep, atrophy 
versus healthy controls. There was no difference in either deep 
or superficial atrophy score between SLE and stroke patients.
Table 1. Subject Characteristics
SLE Stroke
P Value
n (%) or Mean 
(SD) or Median 
(Q1–Q3)
n (%) or Mean 
(SD) or Median 
(Q1–Q3)
n 51 51  
Female patients, n 47 (92%) 47 (92%) 0.99
Age, y 48.8 (14.3) 55.3 (8.9) 0.008
Disease duration, mo 50 (24–148) NA NA
Members of SLEx registry 31 (61%) NA NA
NPSLE 4 (8%) NA NA
BMI, kg/m2 29 (6.5) NA NA
Current smoker 6 (12%) 28 (54.9%) <0.0001
Hypertension 9 (18%) 32 (62.7%) <0.0001
Diabetes mellitus None 2 (3.9%) NA
Medical history of stroke 1 (1.9%) 51 NA
Current steroids 18 (35%) NA NA
Fatigue (score) 5.0 (1.7) NA NA
MMSE (score, max 30) 28 (27–30) NA NA
MoCA (score, max 30) 26 (24–28) NA NA
ACER (score, max 100) 91 (87–94) NA NA
SLICC (score) 0 (0–1) NA NA
SLEDAI-2K (score) 2 (0–4) NA NA
BILAG (score) 2 (1–9) NA NA
ACER indicates Addenbrooke’s Cognitive Examination–Revised; BILAG, 
British Isles Lupus Assessment Group; BMI, body mass index; MMSE, Mini 
Mental State Examination; MoCA, Montreal Cognitive Assessment; NA, not 
applicable; NPSLE, neuropsychiatric SLE; SLE, systemic lupus erythematosus; 
SLEDAI-2K, Systemic Lupus Erythematosus Disease Activity Index; SLEx, 
Scottish Lupus Exchange Registry; and SLICC, Systemic Lupus International 
Collaborating Clinics.
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Association Between Total SVD 
Score and Other Variables
In SLE, the SVD score was associated in univariate analyses 
with age (OR, 1.05; 95% CI, 1.01–1.09), hypertension (OR, 
1.82; 95% CI, 1.13–2.93), higher levels of mean diffusivity 
(OR, 2.58; 95% CI, 1.32–5.06), and lower levels of fractional 
anisotropy (OR, 0.42; 95% CI, 0.22–0.80). The association 
with hypertension did not remain after adjusting for age (Table 
III in the online-only Data Supplement). Higher SVD burden 
was inversely associated with fatigue but not when adjusted 
for age. The total SVD score was not associated with SLE 
activity (by SLE activity scoring tools or blood markers of 
activity), accumulated damage (SLICC), SLE disease dura-
tion, inflammatory markers, or cognitive variables. More PVS 
in the centrum semiovale were associated with higher levels 
of HDL cholesterol (OR, 14.88; CI, 2.76–80.09; Table IV in 
the online-only Data Supplement), which remained significant 
after adjusting for age and body mass index (OR, 16.99; CI, 
2.98–96.66). No other individual SVD feature showed signifi-
cant associations with other variables (vascular risk factors, 
SLE activity, or blood markers).
Neuropsychiatric Systemic Lupus Erythematosus
Patients diagnosed with NPSLE (n=4) had more deep WMH 
compared with SLE (P=0.04; Table V in the online-only Data 
Supplement), but data were limited.
Discussion
We show that patients with SLE have more SVD neuroim-
aging markers, notably PVS and deep WMH, than sex- and 
age-matched healthy controls and more PVS than patients 
with minor stroke patients from the same health region. 
Deep WMH were worse in 4 patients with NPSLE, but the 
number of patients with NPSLE in our study was small that 
limits generalizability. Our patients were not selected on the 
basis of neurological involvement, and only 4 out of 51 were 
diagnosed with NPSLE. Despite the stroke patients being 
slightly older, with far more smokers and hypertensives, the 
SLE patients had more PVS and an equal burden of WMH. 
The higher burden of PVS in SLE patients, in the absence of 
vascular risk factors, is consistent with the known associa-
tion between PVS and plasma markers of inflammation in 
patients with SVD and suggests that inflammation may be 
associated with subclinical microvascular brain damage in 
SLE patients. However, although the present study design 
demonstrates an association between SVD imaging features 
and a systemic inflammatory disease, it cannot identify the 
nature of the inflammation, whether local or vascular/sys-
temic. The study was exploratory, and a larger study, with 
more power to detect differences between groups while also 
accounting for traditional risk factors, is warranted. The 
Table 2. Imaging Biomarkers of SVD in SLE Patients, Healthy Controls, and Stroke Patients
Group Kruskal–Wallis Pairwise Post-Test P Value
SLE (n=51) Stroke (n=51) Controls (n=51) Group P Value SLE–Stroke SLE–Controls Stroke–Controls
Lacunes 0 (0–0) 0 (0–0) 0 (0–0) 0.02   0.01
Microbleeds 0 (0–0) 0 (0–0) 0 (0–0) 0.15    
PVS BG (score 0–4) 2 (2–3) 1 (1–1) 1 (1–1) <0.0001 <0.0001 <0.0001  
PVS CS (score 0–4) 3 (3–4) 1 (1–2) 1 (1–1) <0.0001 <0.0001 <0.0001 0.001
WMH periventricular (score 0–3) 1 (1–1) 1 (1–1) 1 (1–1) 0.48    
WMH deep (score 0–3) 1 (0–1) 1 (0.5–1) 0 (0–1) <0.0001  0.01 0.0007
WMH (total Fazekas score 0–6) 2 (1–2) 2 (1–2.5) 1 (1–2) 0.02  0.05 0.03
Total SVD score (score 0–4) 1 (1–1) 0 (0–1) 0 (0–0) <0.0001 0.02 <0.0001 0.0006
Deep atrophy (score 1–6) 1 (1–2) 1 (1–1) 1 (1–2) 0.14    
Superficial atrophy (score 1–6) 1 (1–2) 1 (1–1) 1 (1–1) 0.006  0.004  
Values are medians (Q1–Q3). The P value compares the individual SVD features across the 3 groups by Kruskal–Wallis test. Post-test comparisons identifies where 
differences exists. Blank cells indicate nonsignificant P values. BG indicates basal ganglia; CS, centrum semiovale; PVS, perivascualr spaces; SLE, systemic lupus 
erythematosus; SVD, small vessel disease; and WMH, white matter hyperintensities.
Figure. Total small vessel disease (SVD) score by age distribu-
tion in systemic lupus erythematosus (SLE), stroke, and healthy 
controls.
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higher burden of SVD also provides a possible explana-
tion for increased stroke risk; a hypothesis that should be 
investigated.
A limitation of the current cross-sectional study design is 
that it cannot ascertain a temporal relationship for the SVD 
markers within the SLE group. A longitudinal study, ide-
ally from initial presentation with SLE, would be required to 
determine the pattern of SVD development in relation to SLE 
activity and duration.
Several cross-sectional studies (reviewed in Wiseman et 
al1), including ≈1200 SLE patients, reported features of SVD, 
such as WMHs and atrophy, but many of these studies focused 
on NPSLE patients, few compared SLE to healthy controls, 
none compared SLE to minor stroke patients, which allows for 
comparison with clinically overt SVD, and none included the 
range of SVD features assessed here with validated scoring 
tools. Longitudinally, a 20-year MRI follow-up study showed 
increased number and volume of WMHs and brain volume 
loss in most of 30 SLE patients studied, but may have reflected 
mainly ageing effects.29 In a shorter follow-up study of 75 
SLE patients, predictors of new or increased WMH included 
antiphospholipid antibodies, SLE damage scores, and higher 
dose of corticosteroids (possibly a marker of higher disease 
activity), and there was more gray and white matter volume 
loss versus controls.30,31
PVS on neuroimaging are associated with inflammatory 
activity.32 PVS were associated with the inflammatory marker 
CRP in a large cohort (n=634) of community-dwelling older 
people (ß=0.12; P=0.048).5 In our study, the total SVD score 
and PVS were not associated with any blood measure of 
inflammation (ESR, CRP, interleukin-6) or with clinical SLE 
disease activity or disease burden score, but this may reflect 
the small sample. However, we note that ≈40% of patients 
had raised ESR and CRP. Moreover, our cross-sectional study 
design did not permit us to associate inflammatory flares over 
time with the evolution, or not, of PVS or WMH. We did not 
select patients on the basis of SLE activity and cannot exclude 
the possibility that blood markers of inflammation (eg, cap-
tured during a flare-up) will associate with PVS in a larger 
or longitudinal study. Chung et al33 also found no associa-
tion between systemic inflammation (measured using a novel 
marker, GlycA) and SLE activity, despite the presence of sys-
temic inflammation.
Perivascular inflammation of the small cerebral vessels 
is a prominent finding in SLE34 at autopsy and in sporadic 
SVD.4 Some studies have noted PVS35,36 on brain imaging in 
SLE patients (n=122), but data are limited, and none com-
pared the total load with a non-SLE comparator group. In 
a recent, but smaller (n=11), postmortem study of vascular 
changes in SLE, one third of subjects had microthrombo-
emboli, glial hyperplasia, neuronal loss, microaneurysms, 
lacunar infarcts and microbleeds, which correlated with 
neuroimaging, including recent subcortical infarcts, lacu-
nes, WMHs, and atrophy; stroke and cognitive impairment 
were more frequent findings among these patients compared 
with the SLE patients who did not have histological evi-
dence of SVD.37
We note an association between higher levels of HDL 
cholesterol and more PVS in the centrum semiovale, which 
remained significant after adjusting for age and body mass 
index. High HDL cholesterol is traditionally considered 
protective against cardiovascular diseases including isch-
emic stroke, but a recent meta-analysis showed that drugs 
designed to boost HDL did not improve cardiovascular 
outcomes.38 Additionally, a gene variation in some people 
impairs HDL uptake, making them susceptible to cardio-
vascular disease despite high HDL.39 In a cohort study40 of 
210 SLE patients followed for 29 months, functional HDL (a 
novel marker of inflammation) was associated with carotid 
plaques (OR, 9.1; 95% CI, 3.3–24.6). Meanwhile, higher 
HDL is associated with increased risk of hemorrhagic stroke 
in the general population (relative risk, 1.17; 95% CI, 1.02–
1.35; 7960 strokes, 1.4 million participants).41 The reason 
why cholesterol might relate to PVS in SLE is unknown and 
could be spurious given our study’s lack of power, but HDL 
can become dysfunctional resulting in inflammation42,43 and 
endothelial dysfunction.44
Our analysis provides support for the concept of a total 
SVD score24,25 as a simple surrogate marker for total brain 
damage because of SVD. The association of deep and super-
ficial atrophy on univariate analysis, but not in adjusted 
analyses, is in agreement with Staals et al24 and suggests that 
atrophy should remain complementary, but not core, in the 
SVD score as atrophy coassociates with age. Our volume 
measure of atrophy (the BTV:ICV ratio) was also associated 
with total SVD burden. Hypertension (dichotomized [data 
not shown] and on a 6-point scale) was also associated with 
the total SVD score, but unlike Staals et al,24 smoking (cur-
rent or ever) was not, although our study was underpowered 
and only 12% of our patients smoked compared with one 
third of theirs.
We did not collect concomitant renal pathology data. Other 
limitations include a potential source of bias as the healthy 
controls were recruited from the community by advertising 
and required to be without known vascular risk factors such as 
hypertension or diabetes mellitus. We may, thus, have influ-
enced the associations of SVD burden in the stroke and SLE 
patients, although few of the SLE patients had hypertension 
or diabetes mellitus. We tried to avoid selection bias in the 
SLE group by recruiting consecutively and hence included 
SLE patients with a range of disease durations and severities. 
A much larger study, sufficiently powered, is now justified to 
assess the influence of traditional vascular risk factors and the 
effects of treatments on SVD burden in SLE. Additionally, 
larger longitudinal studies are needed to fully appreciate the 
significance of SVD in SLE, for example, to elucidate the 
contribution of SLE activity, diet and lifestyle, SLE treat-
ments, or some other variable in causing accelerated brain 
damage in these patients.
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Table I Scanning parameters 
 
56 slices, 24 FOV, Top to bottom (start 1 slice above brain tissue), Straight axials (not AC-PC),      DTI = set fft_xsize + fft_ysize =128 and note locations. 
 
SEQ. NUMBER 1 2 3 4 5 6 7 8 9 
SEQUENCE Loc FLAIR T2 GRE Sag T2 Cube 3D IR PREP 
DTI (32 
directions) 
FSPGR 2 FSPGR 12 
ORIENTATION  AX AX AX SAG COR AX AX AX 
TE  140 102 14  MIN/FUL MIN MIN FULL MIN FULL 
TR  9400 8750 1420 3000  13750   
TI/prep time  2350    500    
FOV  24 24 24 24 24 24 24 24 
SLICE THICK.  5 2.5 2.5 1 1.3 2.5 2.5 2.5 
SLICE GAP  0 0 0 0 0 0 0 0 
Acq. MATRIX  384 x 256 384 x 384 384 x 256 320 x 320 192 x 192 96 x 96 128 x 128 128 x 128 
Padded (R x C)  512 x 512  512 x 512 512 x 512 512 x 512 256 x 256 128 x 128 256 x 256 256 x 256 
Pixel width  0.47 0.47 0.47 0.47 0.94 1.875 0.94 0.94 
Pixel height  0.47 0.47 0.47 0.47 0.94 1.875 0.94 0.94 
Voxel depth  5 2.5 2.5 1 1.3 2.5 2.5 2.5 
Resolution  2.133 pix/mm 2.133 pix/mm 2.133 pix/mm 2.133 pix/mm 1.067 pix/mm 0.533 pix/mm 1.067 pix/mm 1.067 pix/mm 
PHASE FOV   1 1  1 1 1 1 
FREQ. DIR  AP AP AP  SI RL AP AP 
BAND WIDTH  15.63 20.83 12.50  15.63  27.78 27.78 
NEX  1 1 1 1 1 1 1 1 
FLIP ANGLE    20  8  2 12 
NO. SLICES  28 56 56 
1 SLAB 
(180 locs) 
1 SLAB 
(160 locs) 
56 
1 SLAB 
(62 locs) 
1 SLAB 
(62 locs) 
TIME of ACQ. 0:10 6:16 5:59 6:09 5:13 8:12 8:15 00:49 00:49 
Brain Research Imaging Centre, University of Edinburgh. 2104.  www.bric.ed.ac.uk 
3 
 
Table II Blood results for 51 SLE patients  
 
 N (%) or mean ± SD 
or median (Q1–Q3) 
Reference range 
Rheumatological   
C3 (mg / dL) (n=47) 1.2 ± 0.32  0.81–1.57 
C4 (mg / dL) (n=47) 0.19 ± 0.09 0.13–0.39 
Anti-ds-DNA (IU / mL) (n=47) 15 (8.5–33) 0–20 
Inflammatory    
ESR (mm / hr) (n=49) 13 (6–21) 3–15  
CRP (mg / L) (n=46) 2 (1–8) 0–5  
IL-6 (pg / mL) (n=40) 1.72 (1.12–2.37)  
IFN (RQ value)  (n=25) 6.7 (0.60–18.5)  
Endothelial dysfunction   
vWF Ag (IU / mL) (n=46) 1.71 ± 0.66 0.42–1.22 
vWF fVIIIc (IU / mL) (n=46) 1.38 ± 0.45 0.5–1.5  
vWF RCOF (IU / mL) (n=46) 1.37 ± 0.41 0.42–1.22 
Homocysteine (umol / L) (n=45) 17 (15–21) 0–20  
Lipids   
Total cholesterol (mmol / L) (n=49) 5.02 ± 0.95 <5.2 
HDL cholesterol (mmol / L) (n=47) 1.42 ± 0.41 >1 
LDL cholesterol (mmol / L) (n=46) 2.96 ± 0.84 <3.3 
Antibodies   
Anti-cardiolipin IgG (GPL) (n=50) 3.35 (2.20–5.60) 0–13.3 
Anti-cardiolipin IgM (MPL) (n=50) 1.65 (1.10–3.30) 0–9.8  
Lupus anticoagulant (n=47) 5 positive Positive/Negative 
 
Anti-ds-DNA = anti-double stranded DNA, CRP = C-reactive protein, ESR = erythrocyte sedimentation rate, 
HDL = high density lipoprtein, IFN = interferon, IgG = immunoglobulin isotype G, IgM = immunoglobulin 
isotype M, IL-6 = interleukin-6, LDL = low density lipoprotein, vWF Ag = von Willebrand Factor antigen, vWF 
fVIIIc = von Willebrand Factor factor VIIIc, vWF RCOF = von Willebrand Factor ristocetin co-factor 
 
 
 
 
 
 
 
 
 
 
 
 
  
4 
 
Table III Univariate and multivariable associations between total SVD score and other 
variables in SLE patients  
 
 Unadjusted Age adjusted Adjusted for age and 
SLE disease duration 
 OR 95%CI OR 95%CI OR 95%CI 
Vascular risk factors 
Age (years) 1.05 1.01 – 1.09 * -- -- 1.05 1.00 – 1.10 * 
Hypertension (classified) 1.82 1.13 – 2.93 * 1.58 0.95 – 2.63 1.58 0.95 – 2.63 
BMI (kg / m2) 0.97 0.89 – 1.06 0.95 0.87 – 1.04 0.95 0.87 – 1.04 
Disease duration (months) 1.00 0.99 – 1.01 1.00 0.99 – 1.00 -- -- 
Current smoker (Yes/No) 0.91 0.15 – 5.29 1.19 0.19 – 7.32 1.22 0.19 – 7.55 
Ever smoked (Yes/No) 2.06 0.63 – 6.80 2.00 0.67 – 6.62 2.01 0.60 – 6.76 
Steroids (Yes/No) 0.63 0.18 – 2.16 0.62 0.18 – 2.14 0.62 0.18 – 2.13 
Neurological 
Fatigue 0.68 0.47 – 0.98 * 1.04 0.99 – 1.08 1.00 0.99 – 1.00 
Anxiety 0.97 0.87 – 1.08 1.02 0.90 – 1.14 1.02 0.90 – 1.14 
Depression 0.97 0.85 – 1.09 1.01 0.88 – 1.15 1.01 0.88 – 1.15 
MMSE 0.94 0.63 – 1.38 1.05 0.69 – 1.58 1.07 0.69 – 1.67 
MoCA 1.06 0.89 – 1.26 1.11 0.92 – 1.33 1.12 0.93 – 1.36 
ACER 1.01 0.94 – 1.09 1.02 0.95 – 1.11 1.03 0.95 – 1.12 
Rheumatology scores 
SLEDAI-2K 1.01 0.78 – 1.30 1.01 0.78 – 1.31 1.01 0.78 – 1.31 
BILAG 0.95 0.85 – 1.07 0.98 0.87 – 1.11 0.99 0.87 – 1.11 
SLICC 1.14 0.68 – 1.91 0.93 0.53 – 1.62 0.88 0.48 – 1.65 
DTI biomarkers 
MD across 12 tracts (n=47) 2.58 1.32 – 5.06 † 2.32 1.16 – 4.64 * 2.53 1.22 – 5.22 * 
FA across 12 tracts (n=47) 0.42 0.22 – 0.80 †  0.47 0.24 – 0.93 * 0.43 0.21 – 0.88 * 
Bloods 
C3 (mg / dL) (n=47) 1.06 0.15 – 7.56 1.06 0.14 – 8.11 1.14 0.14 – 8.93 
C4 (mg / dL) (n=47) 1.07 0.52 – 2.20 1.14 0.55 – 2.35 1.17 0.56 – 2.47 
Anti-ds-DNA (IU / mL) (n=47) 0.99 0.98 – 1.01 0.99 0.98 – 1.00 0.99 0.98 – 1.01 
ESR (mm / hr) (n=49) 1.03 0.99 – 1.06 1.02 0.98 – 1.06 1.02 0.98 – 1.06 
CRP (mg / L) (n=45) 0.99 0.92 – 1.08 0.99 0.92 – 1.08 1.00 0.92 – 1.08 
IL-6 (pg / mL) (n=40) 0.99 0.71 – 1.40 1.02 0.72 – 1.43 1.02 0.72 – 1.43 
IFN (RQ value)  (n=24) 1.04 0.94 – 1.14 1.04 0.95 – 1.14 1.04 0.93 – 1.16 
vWF Ag (IU / mL) (n=46) 1.21 0.48 – 3.00 0.88 0.33 – 2.30 0.87 0.33 – 2.31 
vWF F8c (IU / mL) (n=46) 2.50 0.66 – 9.45 2.30 0.62 – 8.57 2.31 0.62 – 8.61 
vWF RCOF (IU / mL) (n=46) 2.00 0.46 – 8.56 1.24 0.26 – 5.83 1.25 0.26 – 5.91 
Homocysteine (umol / L) (n=45) 1.03 0.94 – 1.12 1.01 0.92 – 1.11 1.01 0.92 – 1.11 
Tot cholesterol (mmol / L) (n=49) 1.55 0.84 – 2.87 1.37 0.72 – 2.59 1.38 0.73 – 2.62 
HDL cholesterol (mmol / L) (n=47) 1.35 0.32 – 5.74 1.41 0.33 – 6.04 1.39 0.32 – 6.02 
LDL cholesterol (mmol / L) (n=46) 1.72 0.85 – 3.49 1.47 0.71 – 3.01 1.50 0.71 – 3.14 
Anti-cardiolipin IgG (GPL) (n=50) 0.92 0.77 – 1.09 0.93 0.78 – 1.11 0.93 0.78 – 1.10 
Anti-cardiolipin IgM (MPL) (n=50) 1.00 0.95 – 1.06 0.98 0.93 – 1.04  0.98 0.93 – 1.04 
Lupus anticoagulant (n=47) 0.42 0.06 – 2.73 0.30 0.04 – 2.18 0.30 0.04 – 2.15 
* p<0.05, † p<0.01 
 
ACER = Addenbrooke’s Cognitive Examination – Revised, BMI = body mass index, BILAG = British Isles Lupus 
Assessment Group, BTV = brain tissue volume, CRP = C-reactive protein, DTI = diffusion tensor imaging, ESR = 
erythrocyte sedimentation rate, FA = fractional anisotropy, HDL = high density lipoprotein, LDL = low density 
lipoprotein, MD = mean difussivity, MMSE = Mini Mental State Examination, MoCA = Montreal Cognitive Assessment, 
IFN = interferon beta, IL-6 = interleukin-6, ICV = intracranial volume, SLEDAI-2K = systemic lupus erythematosus 
Disease Activity Index, SLICC = Systemic Lupus International Collaborating Clinics, vWF Ag = von Willebrand Factor 
antigen, vWF F8c = von Willebrand Factor VIII, vWF RCOF = von Willebrand Factor ristocen co-factor 
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Table IV  Unadjusted univariable associations between individual SVD features and other 
variables in SLE patients 
 
 PVS BG PVS CS WMH (Total Fazekas) 
 OR 95%CI OR 95%CI OR 95%CI 
Vascular risk factors       
Age (years) 1.02 0.98 – 1.06 1.03 0.99 – 1.07 1.13 1.07 – 1.20 ‡ 
Hypertension (classified) 1.36 0.90 – 2.05 1.25 0.84 – 1.86 1.88 1.20 – 2.94 † 
BMI (kg / m2) 0.97 0.89 – 1.05 0.98 0.91 – 1.07 1.03 0.95 – 1.25 
Disease duration (months) 1.00 0.99 – 1.00 1.00 0.99 – 1.00 1.00 0.99 – 1.00 
Current smoker (Yes/No) 0.87 0.19 – 3.92 0.50 0.11 – 2.34 1.87 0.37 – 9.40 
Ever smoked (Yes/No) 0.82 0.30 – 2.23 0.77 0.27 – 2.18 2.63 0.87 – 7.89 
Steroids (Yes/No) 0.48 0.17 – 1.41 0.74 0.25 – 2.24 1.44 0.47 – 4.36 
Rheumatology scores       
SLEDAI 1.10 0.88 – 1.37 1.04 0.80 – 1.35 1.00 0.78 – 1.29 
BILAG 0.96 0.86 – 1.07 0.93 0.84 – 1.04 0.96 0.86 – 1.07 
SLICC 0.86 0.55 – 1.35 0.92 0.57 – 1.49 1.42 0.88 – 2.28 
Bloods       
C3 (mg / dL) (n=47) 0.35 0.06 – 1.98 1.08 0.22 – 5.29 0.70 0.13 – 3.71 
C4 (mg / dL) (n=47) 0.85 0.45 – 1.62 1.16 0.64 – 2.09 0.79 0.42 – 1.49 
Anti-ds-DNA (IU / mL) (n=47) 1.00 0.99 – 1.02 1.00 0.99 – 1.01 1.00 0.99 – 1.01 
ESR (mm / hr) (n=49) 1.02 0.98 – 1.05 0.99 0.96 – 1.02 1.03 0.99 – 1.06 
CRP (mg / L) (n=45) 1.00 0.99 – 1.03 1.02 0.98 – 1.06 1.02 0.99 – 1.04 
IL-6 (pg / mL) (n=40) 1.04 0.79 – 1.37 0.94 0.71 – 1.24 0.98 0.74 – 1.29 
IFN (RQ value)  (n=24) 0.93 0.86 – 1.00 0.97 0.91 – 1.05 0.98 0.90 – 1.06 
vWF Ag (IU / mL) (n=46) 0.96 0.43 – 2.17 1.56 0.67 – 3.60 1.30 0.56 – 2.99 
vWF F8c (IU / mL) (n=46) 1.39 0.40 – 4.84 2.58 0.69 – 9.64 1.89 0.54 – 6.63 
vWF RCOF (IU / mL) (n=46) 1.07 0.29 – 3.89 1.62 0.42 – 6.21 1.34 0.31 – 5.76 
Homocysteine (umol / L) (n=45) 0.97 0.89 – 1.04 1.02 0.94 – 1.11 1.07 0.98 – 1.16 
Tot cholesterol (mmol / L) (n=49) 1.75 0.98 – 3.12 1.40 0.80 – 2.46  1.31 0.73 – 2.35 
HDL cholesterol (mmol / L) (n=47) 3.30 0.86 – 12.6 14.8 2.76 – 80.0 ‡ 0.95 0.23 – 3.99 
LDL cholesterol (mmol / L) (n=46) 1.89 0.96 – 3.71 1.11 0.58 – 2.12 1.38 0.70 – 2.73 
Anti-cardiolipin IgG (GPL) (n=50) 1.00 0.86 – 1.16 0.94 0.80 – 1.09 0.88 0.75 – 1.04 
Anti-cardiolipin IgM (MPL) (n=50) 1.02 0.97 – 1.08 1.02 0.97 – 1.07 0.99 0.94 – 1.04 
Lupus anticoagulant (n=47) 0.79 0.14 – 4.67 1.23 0.22 – 6.84 0.60 0.11 – 3.22 
* p<0.05, † p<0.01 ‡ p<0.0001 
 
BMI = body mass index, BILAG = British Isles Lupus Assessment Group, BTV = brain tissue volume, CI = 
confidence interval, CRP = C-reactive protein, DTI = diffusion tensor imaging, ESR = erythrocyte 
sedimentation rate, HDL = high density lipoprotein, LDL = low density lipoprotein, IFN = interferon beta, IL-6 
= interleukin-6, ICV = intracranial volume, OR = odds ratio, PVS BG = perivascular spaces in basal ganglia, 
PVS BG = perivascular spaces in centrum semiovale, SLEDAI = systemic lupus erythematosus Disease Activity 
Index, SLICC = Systemic Lupus International Collaborating Clinics, vWF Ag = von Willebrand Factor antigen, 
vWF F8c = von Willebrand Factor VIII, vWF RCOF = von Willebrand Factor ristocen co-factor, WMH = white 
matter hyperintensties 
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Table V Imaging biomarkers of SVD in SLE and NPSLE patients 
 
 SLE NPSLE  
 Median (Q1–Q3) Median (Q1–Q3) p value 
N 47 4  
Lacunes 0 (0–0) 0 (0–0) 0.52 
Microbleeds 0 (0–0) 0 (0–0) 0.71 
PVS BG (score 0–4) 2 (2–3) 2.5 (1.5–3.0) 0.76 
PVS CS (score 0–4) 3 (3–4) 3.0 (1.5–4.0) 0.72 
WMH periventricular (score 0–3) 1 (1–1) 1.5 (0.5–2.5) 0.43 
WMH deep (score 0–3) 1 (0–1) 1.5 (1.0–2.5) 0.04 * 
WMH (total Fazekas score 0–6) 2 (1–2) 3.0 (1.5–5.0) 0.22 
Total SVD score (score 0–4) 1 (1–2) 1.5 (1.0–3.5) 0.43 
Deep atrophy (score 1–6) 1 (1–2) 1.5 (1.0–2.5) 0.49 
Superficial atrophy (score 1–6) 1 (1–1) 1.5 (0.5–2.0) 0.59 
 
* p<0.05 
BG = basal ganglia, CS = centrum semiovale, NPSLE = neurpsychiatric SLE, PVS = perivascualr spaces, SVD 
= small vessel disease, SLE = systemic lupus erythematosus, WMH = white matter hyperintensities. 
 
 
 
Medications 
 
Fifty of 51 SLE patients were taking one or more regular medications for SLE at time of MR 
scanning, including non-steroidal anti-inflammatory drugs (n=2 SLE patients); anti-malarials 
(n=40); immunosupressants (n=30); corticosteroids (n=18); and biological therapy (n=1).  
Additioanlly, one patient was on warfarin, several were on alendronic acid for osteoperosis and 
many were taking pain killers as required.  We cross-checked these self-reported medications 
with records from rheumatology / the NHS. 
 
 
 
